

Einführung der Pathogeninaktivierung für Thrombozytenkonzentrate in der Schweiz

Introduction en Suisse de l'inactivation des agents pathogènes pour les concentrés plaquettaires

Literatur / Références

- 1 Hämovigilanz Jahresbericht 2009, Swissmedic;
www.swissmedic.ch/marktueberwachung/00159/00160/00437/index.html?lang=de
- 2 Eder AF, Kennedy JM, Dy BA, Notari EP, Skeate R, Bachowski G et al. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. *Transfusion*. 2009;49:1554–63.
- 3 Benjamin RJ. Bacterial culture of apheresis platelet products and the residual risk of sepsis. *ISBT Science Series*. 2008;3:133–8.
- 4 Andreu G, Caldani C, Morel P. Reduction of septic transfusion reactions related to bacteria contamination without implementing bacterial detection. *ISBT Science Series*. 2008;3:124–32.
- 5 Lessa F, Leparc GF, Benson K, Sanderson R, Van Beneden CA, Shewmaker PL et al. Fatal group C streptococcal infection due to transfusion of bacterially contaminated pooled platelet unit despite routine bacterial culture screening. *Transfusion*. 2008;48:2177–83.
- 6 Koopman MMW, Van't Ende E, Lieshout-Krikke R, Marcelis J, Smid WM, De Kort D. Bacterial screening of platelet concentrates: result of 2 years active surveillance of transfused positive cultured units released as negative to date. *Vox Sanguinis*. 2009;97:355–7.
- 7 Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: The American Red Cross experience (2004–2006). *Transfusion*. 2007;47:1134–42.
- 8 Ramirez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M. Canadian experience with detection of bacterial contamination in apheresis platelets. *Transfusion*. 2007;47:421–9.
- 9 Ramirez-Arcos S, Chin-Yee I, Hume H, Fearon M, Goldman M, Eckert K, et al. Fatal septic shock associated with transfusion-transmitted *Serratia marcescens*. *Transfusion*. 2006; 46:679–81.
- 10 Schrezenmeier H, Walther-Wenke G, Muller TH, Weinauer F, Younis A, Holland-Letz T, et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. *Transfusion*. 2007; 47:644–52.
- 11 Benjamin RJ, Wagner S: The residual risk of sepsis: modelling bacterial detection in a two bottle culture system and an analysis of sampling error. *Transfusion*. 2007;7:1381–9.
- 12 Cid J, Ramiro L, Bertran S, Martinez N, Claparols M, Maymo R M^a, et al. Efficacy in reducing potassium load in irradiated red cell bags with a potassium adsorption filter. *Transfusion*. 2008;48:1966–70.
- 13 van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euro-SPRITE trial. *Blood*. 2003;101:2426–33.
- 14 McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. *Blood*. 2004;104:1534–41.
- 15 Janetzko K, Cazenave JP, Klüter H, Kientz D, Michel M, Beris P et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. *Transfusion*. 2005;45:1443–52.
- 16 Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, et al. Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. *Br J Haematol*. 2010;150:209–217.
- 17 Lozano M, Knutson F, Tardivel R, Cid J, Maymó RM, Löf H et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. *Br J Haematol*. 2011;153:393–401
- 18 Corash L, Sherman CD. Evaluation of platelet transfusion clinical trials. *Br J Haematol*. 2011;153(4):529–31. Author reply 531–2.
- 19 Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. *Vox Sanguinis*. 2012;102:302–16.
- 20 Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. *Vox Sanguinis*. 2012;103:322–30.

- 21 Hämovigilanz Jahresbericht 2011, Swissmedic:
www.swissmedic.ch/marktueberwachung/00159/00160/00437/index.html?lang=de
- 22 www.swissmedic.ch/marktueberwachung/00159/00160/00435/index.html?lang=de
und www.ihn-org.com/isbt/haemovigilance-wp
- 23 Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. *Transfusion*. 2008;48:1061–71.
- 24 Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with Amotosalen photochemical treatment. *Vox Sanguinis*. 2008;94:315–23.
- 25 Infanti L, Stebler C, Job S, Ruesch M, Gratwohl A, Irsch J, et al. Pathogen-inactivation of platelet components with the INTERCEPT Blood System: a cohort study. *Transfus Apher Sci*. 2011;45:175–81.
- 26 Sigle JP, Infanti L, Studt JD, Martinez M, Stern M, Gratwohl A, et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components *Transfusion* 2012;doi: 10.1111/j.1537-2995.2012.03959.x.